HomeCompareCLBS vs PLD

CLBS vs PLD: Dividend Comparison 2026

CLBS yields 131.33% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLBS wins by $6.49M in total portfolio value
10 years
CLBS
CLBS
● Live price
131.33%
Share price
$0.43
Annual div
$0.56
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$12.99M
Annual income
$5,201,713.69
Full CLBS calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — CLBS vs PLD

📍 CLBS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLBSPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLBS + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLBS pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLBS
Annual income on $10K today (after 15% tax)
$11,163.23/yr
After 10yr DRIP, annual income (after tax)
$4,421,456.64/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, PLD beats the other by $46,514.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLBS + PLD for your $10,000?

CLBS: 50%PLD: 50%
100% PLD50/50100% CLBS
Portfolio after 10yr
$9.75M
Annual income
$5,229,074.93/yr
Blended yield
53.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

CLBS
No analyst data
Altman Z
-42.9
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLBS buys
0
PLD buys
0
No recent congressional trades found for CLBS or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLBSPLD
Forward yield131.33%3.18%
Annual dividend / share$0.56$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$12.99M$6.50M
Annual income after 10y$5,201,713.69$5,256,436.18
Total dividends collected$11.90M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CLBS vs PLD ($10,000, DRIP)

YearCLBS PortfolioCLBS Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$23,833$13,133.21$11,255$555.24+$12.6KCLBS
2$54,754$29,252.94$13,062$1,018.59+$41.7KCLBS
3$121,396$62,809.15$15,903$1,926.67+$105.5KCLBS
4$260,039$130,144.39$20,839$3,823.32+$239.2KCLBS
5$538,781$260,539.45$30,464$8,166.08+$508.3KCLBS
6$1,080,999$504,503.28$52,054$19,457.30+$1.03MCLBS
7$2,102,673$946,004.75$109,886$54,188.93+$1.99MCLBS
8$3,969,574$1,719,713.85$304,030$186,451.18+$3.67MCLBS
9$7,281,647$3,034,202.37$1,166,125$840,813.32+$6.12MCLBS
10$12,993,076$5,201,713.69$6,504,190$5,256,436.18+$6.49MCLBS

CLBS vs PLD: Complete Analysis 2026

CLBSStock

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Full CLBS Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this CLBS vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLBS vs SCHDCLBS vs JEPICLBS vs OCLBS vs KOCLBS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.